1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
    Review

    Yang, J. C. H.; Zhou, C.; Jänne, P. A.; Ramalingam, S. S.; Kim, T. M.; Riely, G. J.; Spira, A. I.; Piotrowska, Z.; Mekhail, T.; Garcia Campelo, M. R.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save
  • Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation
    Review

    Sermer, D.; Elavalakanar, P.; Abramson, J. S.; Palomba, M. L.; Salles, G.; Arnason, J.
    Blood Reviews (2023)

    Fulltext@MSK | Save
  • Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
    Journal Article

    Harding, J. J.; Piha-Paul, S. A.; Shah, R. H.; Murphy, J. J.; Cleary, J. M.; Shapiro, G. I.; Quinn, D. I.; Braña, I.; Moreno, V.; Borad, M.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
    Journal Article

    Bardia, A.; Mayer, I.; Winer, E.; Linden, H. M.; Ma, C. X.; Parker, B. A.; Bellet, M.; Arteaga, C. L.; Cheeti, S.; Gates, M.; more...
    Breast Cancer Research and Treatment (2023)

    Fulltext@MSK | Save
  • Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
    Journal Article

    Petrone, G.; Gaulin, C.; Derkach, A.; Kishtagari, A.; Robson, M. E.; Parameswaran, R.; Stein, E. M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
    Journal Article

    Usmani, S. Z.; Nahi, H.; Legiec, W.; Grosicki, S.; Vorobyev, V.; Spicka, I.; Hungria, V.; Korenkova, S.; Bahlis, N. J.; Flogegard, M.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel
    Journal Article

    Fried, S.; Shouval, R.; Varda-Bloom, N.; Besser, M. J.; Yerushalmi, R.; Shem-Tov, N.; Danylesko, I.; Jacoby, E.; Teihman, S.; Itzhaki, O.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Transfusion guidelines in traumatic brain injury: A systematic review and meta-analysis of the currently available evidence
    Review

    Montgomery, E. Y.; Barrie, U.; Kenfack, Y. J.; Edukugho, D.; Caruso, J. P.; Rail, B.; Hicks, W. H.; Oduguwa, E.; Pernik, M. N.; Tao, J.; more...
    Neurotrauma Reports (2022)

    Fulltext@MSK | Save
  • Transfusion therapy of neonatal and paediatric patients: They are not just little adults
    Review

    Gammon, R. R.; Al-Mozain, N.; Auron, M.; Bocquet, C.; Clem, S.; Gupta, G. K.; Hensch, L.; Klein, N.; Lea, N. C.; Mandal, S.; more...
    Transfusion Medicine (2022)

    Fulltext@MSK | Save